Becton, Dickinson and Company (NYSE:BDX) Shares Sold by Wealth Alliance

Wealth Alliance reduced its holdings in shares of Becton, Dickinson and Company (NYSE:BDXFree Report) by 5.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,228 shares of the medical instruments supplier’s stock after selling 74 shares during the quarter. Wealth Alliance’s holdings in Becton, Dickinson and Company were worth $318,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Fairfield Bush & CO. bought a new position in Becton, Dickinson and Company during the first quarter worth $114,000. Sequoia Financial Advisors LLC lifted its stake in Becton, Dickinson and Company by 11.3% during the first quarter. Sequoia Financial Advisors LLC now owns 2,923 shares of the medical instruments supplier’s stock worth $778,000 after purchasing an additional 297 shares during the last quarter. Brighton Jones LLC lifted its stake in Becton, Dickinson and Company by 8.8% during the first quarter. Brighton Jones LLC now owns 1,383 shares of the medical instruments supplier’s stock worth $368,000 after purchasing an additional 112 shares during the last quarter. Zions Bancorporation N.A. lifted its stake in Becton, Dickinson and Company by 13.0% during the first quarter. Zions Bancorporation N.A. now owns 504 shares of the medical instruments supplier’s stock worth $134,000 after purchasing an additional 58 shares during the last quarter. Finally, Mather Group LLC. lifted its stake in Becton, Dickinson and Company by 26.0% during the first quarter. Mather Group LLC. now owns 1,346 shares of the medical instruments supplier’s stock worth $358,000 after purchasing an additional 278 shares during the last quarter. 86.72% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP Richard Byrd sold 2,156 shares of the firm’s stock in a transaction on Tuesday, November 28th. The stock was sold at an average price of $238.47, for a total transaction of $514,141.32. Following the transaction, the executive vice president now directly owns 4,120 shares of the company’s stock, valued at $982,496.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.31% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on BDX shares. Piper Sandler reduced their price objective on Becton, Dickinson and Company from $305.00 to $280.00 and set an “overweight” rating on the stock in a research note on Friday, November 10th. TheStreet lowered Becton, Dickinson and Company from a “b” rating to a “c+” rating in a research report on Thursday, November 9th. Raymond James increased their target price on Becton, Dickinson and Company from $269.00 to $275.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 3rd. Morgan Stanley dropped their target price on Becton, Dickinson and Company from $310.00 to $280.00 and set an “overweight” rating on the stock in a research report on Monday, December 4th. Finally, Barclays increased their target price on Becton, Dickinson and Company from $301.00 to $305.00 and gave the stock an “overweight” rating in a research report on Monday, February 5th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, Becton, Dickinson and Company presently has a consensus rating of “Moderate Buy” and a consensus target price of $279.17.

Get Our Latest Analysis on BDX

Becton, Dickinson and Company Price Performance

Shares of BDX opened at $243.75 on Monday. The firm has a market capitalization of $70.42 billion, a price-to-earnings ratio of 57.76, a price-to-earnings-growth ratio of 2.01 and a beta of 0.43. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.64 and a current ratio of 1.08. Becton, Dickinson and Company has a one year low of $228.62 and a one year high of $287.32. The stock’s fifty day moving average is $238.69 and its 200-day moving average is $253.43.

Becton, Dickinson and Company (NYSE:BDXGet Free Report) last issued its quarterly earnings results on Thursday, February 1st. The medical instruments supplier reported $2.68 EPS for the quarter, beating analysts’ consensus estimates of $2.39 by $0.29. The company had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.73 billion. Becton, Dickinson and Company had a return on equity of 13.57% and a net margin of 6.44%. The company’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same period last year, the company earned $2.98 earnings per share. Equities analysts anticipate that Becton, Dickinson and Company will post 12.95 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 29th. Stockholders of record on Friday, March 8th will be issued a dividend of $0.95 per share. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.56%. The ex-dividend date of this dividend is Thursday, March 7th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 90.05%.

About Becton, Dickinson and Company

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Further Reading

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.